OLMA insider transaction filings
Olema Pharmaceuticals, Inc. — 48 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-27. Screen OLMA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-27 | 4 | Harmon Cyrus — Director | Sale (S): 12,500 @ $11.58 · Sale (S): 12,500 @ $11.71 | EDGAR |
| 2026-06-23 | 4 | Raman Prakash — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Harmon Cyrus — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Hrustanovic Gorjan — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Larson Yi — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Graham G. Walmsley — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Horning Sandra — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Garland J. Scott — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | CLARK IAN T — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | BUTITTA CYNTHIA M — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | RAPPAPORT ANDREW — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | BVF PARTNERS L P/IL — Director BIOTECHNOLOGY VALUE FUND L P — Director BVF I GP LLC — Director BIOTECHNOLOGY VALUE FUND II LP — Director BVF II GP LLC — Director Biotechnology Value Trading Fund OS LP — Director BVF Partners OS Ltd. — Director BVF GP HOLDINGS LLC — Director BVF INC/IL — Director LAMPERT MARK N — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-04-29 | 4 | Raman Prakash — Director | Grant/award (A): 2,911 (derivative) @ $0 · Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Mitchell Shawnte — CHIEF LEGAL OFFICER | Option exercise (M): 15,000 @ $4.37 · Sale (S): 15,000 @ $23.01 · Option exercise (M): 25,000 @ $4.37 · Sale (S): 24,767 @ $24.25 · Sale (S): 233 @ $24.69 · Option exercise (M): 15,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-17 | 4 | Austin Sasha Lu — VP of Finance and Controller | Grant/award (A): 11,700 @ $0 · Grant/award (A): 29,250 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Zojwalla Naseem — CHIEF MEDICAL OFFICER | Grant/award (A): 250,000 (derivative) @ $0 · Grant/award (A): 106,250 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Bohen Sean — PRESIDENT AND CEO, Director | Grant/award (A): 850,000 (derivative) @ $0 · Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Myles David C. — CH. DISCOV. & NON-CLIN DEV OFF | Grant/award (A): 250,000 (derivative) @ $0 · Grant/award (A): 106,250 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Mitchell Shawnte — CHIEF LEGAL OFFICER | Grant/award (A): 220,000 (derivative) @ $0 · Grant/award (A): 56,250 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Harmon Cyrus — Director | Sale (S): 10,000 @ $26.88 | EDGAR |
| 2026-01-16 | 4 | Harmon Cyrus — Director | Sale (S): 3,489 @ $29.12 | EDGAR |
| 2026-01-15 | 4 | Kovacs Shane William Charles — CH. OPERATING & FINANCIAL OFF. | Sale (S): 3,822 @ $28.01 · Sale (S): 100,000 @ $28.73 | EDGAR |
| 2026-01-14 | 4 | Myles David C. — CH. DISCOV. & NON-CLIN DEV OFF | Sale (S): 10,000 @ $28.34 · Option exercise (M): 50,000 @ $4.87 · Sale (S): 49,800 @ $27.60 · Sale (S): 200 @ $28.49 · Option exercise (M): 50,000 @ $4.87 · Sale (S): 14,997 @ $28.60 · +3 more | EDGAR |
| 2025-12-30 | 4 | Bohen Sean — President and CEO, Director | Gift (G): 8,500 @ $0 | EDGAR |
| 2025-12-29 | 4 | Harmon Cyrus — Director | Sale (S): 2,881 @ $28.53 | EDGAR |
| 2025-12-23 | 4 | Zojwalla Naseem — Chief Medical Officer | Option exercise (M): 40,000 @ $15.25 · Sale (S): 57,079 @ $28.03 · Sale (S): 12,921 @ $28.93 · Option exercise (M): 42,818 @ $15.25 · Option exercise (M): 7,182 @ $7.02 · Sale (S): 100,000 @ $28.04 · +6 more | EDGAR |
| 2025-12-23 | 4 | Myles David C. — CH. DISCOV. & NON-CLIN DEV OFF | Sale (S): 1,225 @ $28.08 · Sale (S): 43,729 @ $30.40 · Sale (S): 6,046 @ $31.39 · Gift (G): 9,000 @ $0 | EDGAR |
| 2025-12-23 | 4 | CLARK IAN T — Director | Option exercise (M): 209,690 @ $4.41 · Option exercise (M): 21,520 @ $3.61 · Option exercise (M): 21,520 @ $7.84 · Option exercise (M): 12,070 @ $4.08 · Sale (S): 29,904 @ $28.83 · Sale (S): 193,056 @ $29.71 · +5 more | EDGAR |
| 2025-12-09 | 4 | Kovacs Shane William Charles — CH. OPERATING & FINANCIAL OFF. | Gift (G): 75,000 @ $0 | EDGAR |
| 2025-12-01 | 4 | Kovacs Shane William Charles — CH. OPERATING & FINANCIAL OFF. | Gift (G): 225,000 @ $0 | EDGAR |
| 2025-11-25 | 4 | RAPPAPORT ANDREW — Director | Option exercise (M): 35,868 @ $0.39 · Gift (G): 35,868 @ $0 · Option exercise (M): 35,868 (derivative) @ $0 | EDGAR |
| 2025-09-18 | 4 | Harmon Cyrus — Director | Sale (S): 10,000 @ $8.04 · Sale (S): 10,000 @ $8.33 · Sale (S): 1,914 @ $8.08 · Sale (S): 3,086 @ $8.32 | EDGAR |
| 2025-06-13 | 4 | Larson Yi — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Hrustanovic Gorjan — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Graham G. Walmsley — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Harmon Cyrus — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Horning Sandra — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Garland J. Scott — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | CLARK IAN T — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | BUTITTA CYNTHIA M — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | RAPPAPORT ANDREW — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | BVF PARTNERS L P/IL — Director BIOTECHNOLOGY VALUE FUND L P — Director BVF I GP LLC — Director BIOTECHNOLOGY VALUE FUND II LP — Director BVF II GP LLC — Director Biotechnology Value Trading Fund OS LP — Director BVF Partners OS Ltd. — Director BVF GP HOLDINGS LLC — Director BVF INC/IL — Director LAMPERT MARK N — Director | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-05-13 | 4/A | Graham G. Walmsley — Director | Holdings only — no transactions reported | EDGAR |
| 2025-03-03 | 4 | Myles David C. — CH. DISCOV. & NON-CLIN DEV OFF | Grant/award (A): 205,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Zojwalla Naseem — CHIEF MEDICAL OFFICER | Grant/award (A): 205,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Bohen Sean — PRESIDENT AND CEO, Director | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Mitchell Shawnte — CHIEF LEGAL OFFICER | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Kovacs Shane William Charles — CH. OPERATING & FINANCIAL OFF. | Grant/award (A): 320,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Olema Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-26 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2026-04-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OLMA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →